The optimal concentration of siRNA for gene silencing in primary cultured astrocytes and microglial cells of rats.
BACKGROUND
Small interfering RNAs (siRNAs) have been used to knockdown specific gene expression in various cells. Astrocytes and microglial cells play a key role in fundamental central nervous system functions and in chronic neuroinflammation. The aims of this study were to determine the optimal concentration of siRNA demonstrating efficient transfection and inhibition of gene expression via RNA interference (RNAi) and lower cytotoxicity, in primary cultured astrocytes and microglial cells of rats.


METHODS
Astrocytes and microglial cells were isolated from the cerebral cortices of 2-day-old rats. Both the cells were transfected using transfection reagent (Lipofectamine™ 2000), and fluorescein-labeled double-stranded RNA (dsRNA) or siRNA targeting green fluorescent protein. Transfection efficiency and cytotoxicity of dsRNA, and the degrees of RNAi induced by siRNA in these cells, were evaluated at various concentrations of RNA.


RESULTS
Transfection efficiencies of dsRNA in both astrocytes and microglial cells were significantly higher (P < 0.05) at the concentrations of 20, 40, and 80 nM than at the concentrations of 0, 5, and 10 nM. There were no significant cytotoxicities within the applied concentrations of dsRNA (0-80 nM). The degrees of RNAi induced by siRNA were significantly higher (P < 0.05) at the concentrations of 5, 10, 20, 40, 80 nM, and 20, 40, 80 nM in astrocytes and microglial cells, respectively, compared with the control (0 nM).


CONCLUSIONS
The siRNA concentration of 20 nM may be appropriate to induce RNAi in both astrocytes and microglial cells, while demonstrating low cytotoxicity, high transfection efficiency, and effective RNAi.
Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kyeong Ho
KH
Ki
Do Yang
DY
Park
Soo Han
SH
Lee
Nam Yun
NY
Kim
Byung Moon
BM
Choi
Gyu Jeong
GJ
Noh
Stem Cells. 2006 Jun;24(6):1467-75
16456133
BMC Mol Biol. 2008 Jun 24;9:60
18577207
J Neurosci. 2002 Nov 15;22(22):9980-9
12427855
Mol Pain. 2005 Sep 28;1:29
16191203
Genes Dev. 2001 Mar 1;15(5):485-90
11238371
RNA. 2006 Jul;12(7):1179-87
16682560
J Biol Chem. 2005 Jun 24;280(25):24022-34
15849186
Pain. 2001 Feb 1;90(1-2):1-6
11166964
Br J Anaesth. 2005 Dec;95(6):803-10
16227338
Chembiochem. 2001 Apr 2;2(4):239-45
11828450
Nat Biotechnol. 2003 Jun;21(6):635-7
12754523
Nat Methods. 2006 Mar;3(3):199-204
16489337
Nat Biotechnol. 2009 Jun;27(6):549-55
19465925
Methods Mol Biol. 2010;623:383-95
20217565
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
6606682
Proc Natl Acad Sci U S A. 2003 May 27;100(11):6347-52
12746500
BMC Neurosci. 2002 Nov 07;3:18
12423556
Curr Protoc Neurosci. 2001 May;Chapter 7:Unit7.18
18428528
Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1892-7
14769924
Pain. 2001 Sep;93(3):201-205
11514078
J Neurotrauma. 1995 Dec;12(6):1003-14
8742129
Nat Rev Genet. 2001 Feb;2(2):110-9
11253050
J Neurosci. 2001 Apr 15;21(8):2808-19
11306633
Nat Cell Biol. 2003 Sep;5(9):834-9
12942087
J Mol Biol. 2003 Apr 4;327(4):761-6
12654261